Gilead Sciences has secured up to $210 million in financing from life sciences investment company Abingworth to help support the development of its antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) in non-small cell lung cancer, the venture capital firm announced Thursday.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,